Cargando…
Modulating asthma–COPD overlap responses with IL-17 inhibition
BACKGROUND: IL-17 is a modulator of the inflammatory response and is implicated in lung remodeling in both asthma and chronic obstructive pulmonary disease (COPD). Well as and probably in patients with asthma–COPD overlap (ACO). METHODS: In this study, we evaluated the response of the airways and al...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641519/ https://www.ncbi.nlm.nih.gov/pubmed/37965351 http://dx.doi.org/10.3389/fimmu.2023.1271342 |
_version_ | 1785146786134884352 |
---|---|
author | Camargo, Leandro do Nascimento Righetti, Renato Fraga de Almeida, Francine Maria dos Santos, Tabata Maruyama Fukuzaki, Silvia Martins, Nilo Arthur Bezerra Barbeiro, Miguel Cantadori Saraiva-Romanholo, Beatriz Mangueira Lopes, Fernanda Degobbi Tenorio Quirino dos Santos Leick, Edna Aparecida Prado, Carla Máximo Tibério, Iolanda de Fátima Lopes Calvo |
author_facet | Camargo, Leandro do Nascimento Righetti, Renato Fraga de Almeida, Francine Maria dos Santos, Tabata Maruyama Fukuzaki, Silvia Martins, Nilo Arthur Bezerra Barbeiro, Miguel Cantadori Saraiva-Romanholo, Beatriz Mangueira Lopes, Fernanda Degobbi Tenorio Quirino dos Santos Leick, Edna Aparecida Prado, Carla Máximo Tibério, Iolanda de Fátima Lopes Calvo |
author_sort | Camargo, Leandro do Nascimento |
collection | PubMed |
description | BACKGROUND: IL-17 is a modulator of the inflammatory response and is implicated in lung remodeling in both asthma and chronic obstructive pulmonary disease (COPD). Well as and probably in patients with asthma–COPD overlap (ACO). METHODS: In this study, we evaluated the response of the airways and alveolar septa to anti-IL-17 treatment in an ACO model. Fifty-six male BALB/c mice were sensitized with ovalbumin (OVA group), received porcine pancreatic elastase (PPE group), or both (ACO group). Mice were then treated with either anti-IL-17 monoclonal antibody or saline. We evaluated hyperresponsiveness, bronchoalveolar lavage fluid (BALF) cell counts, and mean alveolar diameter. We quantified inflammatory, response, extracellular matrix remodeling, oxidative stress markers, and signaling pathway markers. RESULTS: Anti-IL-17 treatment in the ACO anti-IL-17 group reduced the maximum response of respiratory system Rrs, Ers, Raw, Gtis, this when compared to the ACO group (p<0.05). There was a reduction in the total number of inflammatory cells, neutrophils, and macrophages in the BALF in the ACO anti-IL-17 group compared to the ACO group (p<0.05). There was attenuated dendritic cells, CD4+, CD8+, FOXP3, IL-1β, IL-2, IL-6, IL-13, IL-17, IL-33 in ACO anti-IL-17 group in airway and alveolar septum compared to the ACO group (p<0.05). We observed a reduction of MMP-9, MMP-12, TIMP-1, TGF-β, collagen type I in ACO anti-IL-17 group in airway and alveolar septum compared to the ACO group (p < 0.05). We also observed a reduction of iNOS and 8-iso-PGF2α in the airways and in the alveolar septum was reduced in the ACO anti-IL-17group compared to the ACO group (p < 0.05). Regarding the signaling pathways, NF-kB, ROCK-1, and ROCK-2 in the airway and alveolar septum were attenuated in the ACO anti-IL-17 group when compared to the ACO group (p<0.05). CONCLUSIONS: Our results suggest that inhibiting IL-17 modulates cell-associated cytokine production in lung tissue, extracellular matrix remodeling, and oxidative stress in ACO through the modulation of NF-kB and FOXP3. |
format | Online Article Text |
id | pubmed-10641519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106415192023-11-14 Modulating asthma–COPD overlap responses with IL-17 inhibition Camargo, Leandro do Nascimento Righetti, Renato Fraga de Almeida, Francine Maria dos Santos, Tabata Maruyama Fukuzaki, Silvia Martins, Nilo Arthur Bezerra Barbeiro, Miguel Cantadori Saraiva-Romanholo, Beatriz Mangueira Lopes, Fernanda Degobbi Tenorio Quirino dos Santos Leick, Edna Aparecida Prado, Carla Máximo Tibério, Iolanda de Fátima Lopes Calvo Front Immunol Immunology BACKGROUND: IL-17 is a modulator of the inflammatory response and is implicated in lung remodeling in both asthma and chronic obstructive pulmonary disease (COPD). Well as and probably in patients with asthma–COPD overlap (ACO). METHODS: In this study, we evaluated the response of the airways and alveolar septa to anti-IL-17 treatment in an ACO model. Fifty-six male BALB/c mice were sensitized with ovalbumin (OVA group), received porcine pancreatic elastase (PPE group), or both (ACO group). Mice were then treated with either anti-IL-17 monoclonal antibody or saline. We evaluated hyperresponsiveness, bronchoalveolar lavage fluid (BALF) cell counts, and mean alveolar diameter. We quantified inflammatory, response, extracellular matrix remodeling, oxidative stress markers, and signaling pathway markers. RESULTS: Anti-IL-17 treatment in the ACO anti-IL-17 group reduced the maximum response of respiratory system Rrs, Ers, Raw, Gtis, this when compared to the ACO group (p<0.05). There was a reduction in the total number of inflammatory cells, neutrophils, and macrophages in the BALF in the ACO anti-IL-17 group compared to the ACO group (p<0.05). There was attenuated dendritic cells, CD4+, CD8+, FOXP3, IL-1β, IL-2, IL-6, IL-13, IL-17, IL-33 in ACO anti-IL-17 group in airway and alveolar septum compared to the ACO group (p<0.05). We observed a reduction of MMP-9, MMP-12, TIMP-1, TGF-β, collagen type I in ACO anti-IL-17 group in airway and alveolar septum compared to the ACO group (p < 0.05). We also observed a reduction of iNOS and 8-iso-PGF2α in the airways and in the alveolar septum was reduced in the ACO anti-IL-17group compared to the ACO group (p < 0.05). Regarding the signaling pathways, NF-kB, ROCK-1, and ROCK-2 in the airway and alveolar septum were attenuated in the ACO anti-IL-17 group when compared to the ACO group (p<0.05). CONCLUSIONS: Our results suggest that inhibiting IL-17 modulates cell-associated cytokine production in lung tissue, extracellular matrix remodeling, and oxidative stress in ACO through the modulation of NF-kB and FOXP3. Frontiers Media S.A. 2023-10-27 /pmc/articles/PMC10641519/ /pubmed/37965351 http://dx.doi.org/10.3389/fimmu.2023.1271342 Text en Copyright © 2023 Camargo, Righetti, de Almeida, Santos, Fukuzaki, Martins, Barbeiro, Saraiva-Romanholo, Lopes, Leick, Prado and Tibério https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Camargo, Leandro do Nascimento Righetti, Renato Fraga de Almeida, Francine Maria dos Santos, Tabata Maruyama Fukuzaki, Silvia Martins, Nilo Arthur Bezerra Barbeiro, Miguel Cantadori Saraiva-Romanholo, Beatriz Mangueira Lopes, Fernanda Degobbi Tenorio Quirino dos Santos Leick, Edna Aparecida Prado, Carla Máximo Tibério, Iolanda de Fátima Lopes Calvo Modulating asthma–COPD overlap responses with IL-17 inhibition |
title | Modulating asthma–COPD overlap responses with IL-17 inhibition |
title_full | Modulating asthma–COPD overlap responses with IL-17 inhibition |
title_fullStr | Modulating asthma–COPD overlap responses with IL-17 inhibition |
title_full_unstemmed | Modulating asthma–COPD overlap responses with IL-17 inhibition |
title_short | Modulating asthma–COPD overlap responses with IL-17 inhibition |
title_sort | modulating asthma–copd overlap responses with il-17 inhibition |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641519/ https://www.ncbi.nlm.nih.gov/pubmed/37965351 http://dx.doi.org/10.3389/fimmu.2023.1271342 |
work_keys_str_mv | AT camargoleandrodonascimento modulatingasthmacopdoverlapresponseswithil17inhibition AT righettirenatofraga modulatingasthmacopdoverlapresponseswithil17inhibition AT dealmeidafrancinemaria modulatingasthmacopdoverlapresponseswithil17inhibition AT dossantostabatamaruyama modulatingasthmacopdoverlapresponseswithil17inhibition AT fukuzakisilvia modulatingasthmacopdoverlapresponseswithil17inhibition AT martinsniloarthurbezerra modulatingasthmacopdoverlapresponseswithil17inhibition AT barbeiromiguelcantadori modulatingasthmacopdoverlapresponseswithil17inhibition AT saraivaromanholobeatrizmangueira modulatingasthmacopdoverlapresponseswithil17inhibition AT lopesfernandadegobbitenorioquirinodossantos modulatingasthmacopdoverlapresponseswithil17inhibition AT leickednaaparecida modulatingasthmacopdoverlapresponseswithil17inhibition AT pradocarlamaximo modulatingasthmacopdoverlapresponseswithil17inhibition AT tiberioiolandadefatimalopescalvo modulatingasthmacopdoverlapresponseswithil17inhibition |